Is BIMI International Medical, Inc. overvalued or undervalued?

Jun 25 2025 08:53 AM IST
share
Share Via
As of October 1, 2023, BIMI International Medical, Inc. is considered overvalued with a price-to-earnings ratio of 25.4, significantly higher than peers like HCA Healthcare and Tenet Healthcare, and its stock performance has not exceeded the Sensex.
As of 1 October 2023, BIMI International Medical, Inc. has moved from fair to overvalued. The company's current price-to-earnings ratio stands at 25.4, while its price-to-book ratio is 3.1, and the price-to-sales ratio is 5.6, indicating a premium valuation compared to its earnings and assets.

In comparison to peers such as HCA Healthcare, which has a price-to-earnings ratio of 15.2, and Tenet Healthcare with a price-to-sales ratio of 0.6, BIMI's ratios suggest it is overvalued in the current market environment. Recent stock performance has not outpaced the Sensex, further reinforcing the notion that the stock may be priced too high relative to its fundamentals.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News